Company newsBIIB
Explain this story: Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast
Helus Pharma (operating as Cybin Inc.) CEO Michael Halstead will participate in a webcast fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company is advancing HLP003, a Phase 3 novel serotonergic agonist (NSA) with FDA Breakthrough Therapy Designation for major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder. This participation highlights the company's late-stage pipeline for mental health conditions.
OtherStock TitanSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Helus Pharma (operating as Cybin Inc.) CEO Michael Halstead will participate in a webcast fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026. The company is advancing HLP003, a Phase 3 novel serotonergic agonist (NSA) with FDA Breakthrough Therapy Designation for major depressive disorder, and HLP004, a Phase 2 NSA for generalized anxiety disorder. This participation highlights the company's late-stage pipeline for mental health conditions.
Article tone: Neutral This describes the words the journalist used. It is not a prediction, and not advice.